2025 Q3-regnskab
87 dage siden52 min
Ordredybde
Antal
Køb
0
Sælg
Antal
0
Seneste handel
| Tid | Pris | Antal | Købere | Sælgere |
|---|---|---|---|---|
| - | - | - | - |
Højest
46,34VWAP
Lavest
43,43OmsætningAntal
485,8 10.960.692
VWAP
Højest
46,34Lavest
43,43OmsætningAntal
485,8 10.960.692
Mæglerstatistik
Ingen data fundet
Corporate Actions
Data hentes fra FactSet, Quartr| Næste begivenhed | |
|---|---|
| 2025 Q4-regnskab | 13. feb. |
| Tidligere begivenheder | ||
|---|---|---|
| Ekstraordinær generalforsamling 2025 | 12. nov. 2025 | |
| 2025 Q3-regnskab | 6. nov. 2025 | |
| 2025 Q2-regnskab | 1. aug. 2025 | |
| 2025 Q1-regnskab | 1. maj 2025 | |
| Årlig generalforsamling 2025 | 30. apr. 2025 |
Andre har kigget på
Shareville
Deltag i samtalen med SharevilleBliv en del af vores forum for investorer. Følg andre, og diskuter aktier og fonde.
Log ind
·27. jan.Mere end fordoblet i værdi siden 20.11.2025.
10. dec. 202510. dec. 2025SVENSKE “NANEXA” INDGÅR AFTALE MED MODERNA PÅ OP MOD 500.000.000 USD + royalties på fremtidige produkter! Kæmpe nyheder: Nanexa and Moderna enter into license and option agreement for the development of PharmaShell®-based products The agreement covers the development of up to five undisclosed compounds. Nanexa will receive an upfront payment of USD 3 million and is entitled to up to USD 500 million in potential milestone payments as well as a tiered single-digit royalty on product sales. Nanexa AB (publ), a leader in long-acting injectable drug delivery solutions, has today announced the signing of a license and option agreement with Moderna, Inc. (Nasdaq: MRNA). Under the agreement, Moderna receives a license to use Nanexa’s proprietary PharmaShell® drug delivery platform with its first selected compound and holds options to obtain licenses for up to four additional compounds. As part of the agreement, Nanexa will receive an upfront payment of USD 3 million. The collaboration aims to assess the potential of the PharmaShell® technology to enhance the release profile of Moderna’s selected compounds. If Moderna exercises its options for additional compounds following preclinical evaluation, each option would trigger a pre-negotiated license. The overall deal structure includes development and commercial milestone payments to Nanexa of up to a total of USD 500 million, as well as a tiered single-digit royalty on future product sales. “We are excited to partner with Moderna, a pioneer and leader in the field of mRNA medicines, to explore the potential of our PharmaShell® platform and to support the development of improved products for Moderna,” said David Westberg, CEO of Nanexa. “This agreement underscores the versatility of PharmaShell and its potential to address key challenges in the delivery of advanced biologics.” The PharmaShell® technology, based on atomic layer deposition (ALD), enables precise encapsulation of active pharmaceutical ingredients, offering tailored release profiles and improved product stability. Nanexa’s business model combines internal product development with strategic partnerships and technology licensing to leading pharmaceutical companies.
Kommentarerne ovenfor kommer fra Nordnets sociale netværk Shareville og er ikke blevet redigeret eller gennemgået af Nordnet. Det betyder ikke, at Nordnet giver investeringsrådgivning eller investeringsanbefalinger. Nordnet påtager sig ikke noget ansvar for kommentarerne.
Nyheder
Nyheder og/eller generelle investeringsanbefalinger eller et uddrag af disse på denne side og i relaterede links er produceret og leveret af den angivne leverandør. Nordnet har ikke deltaget i udarbejdelsen af materialet, og vi har ikke gennemgået eller foretaget ændringer i materialet. Læs mere om investeringsanbefalinger.
2025 Q3-regnskab
87 dage siden52 min
Nyheder
Nyheder og/eller generelle investeringsanbefalinger eller et uddrag af disse på denne side og i relaterede links er produceret og leveret af den angivne leverandør. Nordnet har ikke deltaget i udarbejdelsen af materialet, og vi har ikke gennemgået eller foretaget ændringer i materialet. Læs mere om investeringsanbefalinger.
Shareville
Deltag i samtalen med SharevilleBliv en del af vores forum for investorer. Følg andre, og diskuter aktier og fonde.
Log ind
- ·27. jan.Mere end fordoblet i værdi siden 20.11.2025.
- 10. dec. 202510. dec. 2025SVENSKE “NANEXA” INDGÅR AFTALE MED MODERNA PÅ OP MOD 500.000.000 USD + royalties på fremtidige produkter! Kæmpe nyheder: Nanexa and Moderna enter into license and option agreement for the development of PharmaShell®-based products The agreement covers the development of up to five undisclosed compounds. Nanexa will receive an upfront payment of USD 3 million and is entitled to up to USD 500 million in potential milestone payments as well as a tiered single-digit royalty on product sales. Nanexa AB (publ), a leader in long-acting injectable drug delivery solutions, has today announced the signing of a license and option agreement with Moderna, Inc. (Nasdaq: MRNA). Under the agreement, Moderna receives a license to use Nanexa’s proprietary PharmaShell® drug delivery platform with its first selected compound and holds options to obtain licenses for up to four additional compounds. As part of the agreement, Nanexa will receive an upfront payment of USD 3 million. The collaboration aims to assess the potential of the PharmaShell® technology to enhance the release profile of Moderna’s selected compounds. If Moderna exercises its options for additional compounds following preclinical evaluation, each option would trigger a pre-negotiated license. The overall deal structure includes development and commercial milestone payments to Nanexa of up to a total of USD 500 million, as well as a tiered single-digit royalty on future product sales. “We are excited to partner with Moderna, a pioneer and leader in the field of mRNA medicines, to explore the potential of our PharmaShell® platform and to support the development of improved products for Moderna,” said David Westberg, CEO of Nanexa. “This agreement underscores the versatility of PharmaShell and its potential to address key challenges in the delivery of advanced biologics.” The PharmaShell® technology, based on atomic layer deposition (ALD), enables precise encapsulation of active pharmaceutical ingredients, offering tailored release profiles and improved product stability. Nanexa’s business model combines internal product development with strategic partnerships and technology licensing to leading pharmaceutical companies.
Kommentarerne ovenfor kommer fra Nordnets sociale netværk Shareville og er ikke blevet redigeret eller gennemgået af Nordnet. Det betyder ikke, at Nordnet giver investeringsrådgivning eller investeringsanbefalinger. Nordnet påtager sig ikke noget ansvar for kommentarerne.
Ordredybde
Antal
Køb
0
Sælg
Antal
0
Seneste handel
| Tid | Pris | Antal | Købere | Sælgere |
|---|---|---|---|---|
| - | - | - | - |
Højest
46,34VWAP
Lavest
43,43OmsætningAntal
485,8 10.960.692
VWAP
Højest
46,34Lavest
43,43OmsætningAntal
485,8 10.960.692
Mæglerstatistik
Ingen data fundet
Andre har kigget på
Corporate Actions
Data hentes fra FactSet, Quartr| Næste begivenhed | |
|---|---|
| 2025 Q4-regnskab | 13. feb. |
| Tidligere begivenheder | ||
|---|---|---|
| Ekstraordinær generalforsamling 2025 | 12. nov. 2025 | |
| 2025 Q3-regnskab | 6. nov. 2025 | |
| 2025 Q2-regnskab | 1. aug. 2025 | |
| 2025 Q1-regnskab | 1. maj 2025 | |
| Årlig generalforsamling 2025 | 30. apr. 2025 |
2025 Q3-regnskab
87 dage siden52 min
Nyheder
Nyheder og/eller generelle investeringsanbefalinger eller et uddrag af disse på denne side og i relaterede links er produceret og leveret af den angivne leverandør. Nordnet har ikke deltaget i udarbejdelsen af materialet, og vi har ikke gennemgået eller foretaget ændringer i materialet. Læs mere om investeringsanbefalinger.
Corporate Actions
Data hentes fra FactSet, Quartr| Næste begivenhed | |
|---|---|
| 2025 Q4-regnskab | 13. feb. |
| Tidligere begivenheder | ||
|---|---|---|
| Ekstraordinær generalforsamling 2025 | 12. nov. 2025 | |
| 2025 Q3-regnskab | 6. nov. 2025 | |
| 2025 Q2-regnskab | 1. aug. 2025 | |
| 2025 Q1-regnskab | 1. maj 2025 | |
| Årlig generalforsamling 2025 | 30. apr. 2025 |
Shareville
Deltag i samtalen med SharevilleBliv en del af vores forum for investorer. Følg andre, og diskuter aktier og fonde.
Log ind
- ·27. jan.Mere end fordoblet i værdi siden 20.11.2025.
- 10. dec. 202510. dec. 2025SVENSKE “NANEXA” INDGÅR AFTALE MED MODERNA PÅ OP MOD 500.000.000 USD + royalties på fremtidige produkter! Kæmpe nyheder: Nanexa and Moderna enter into license and option agreement for the development of PharmaShell®-based products The agreement covers the development of up to five undisclosed compounds. Nanexa will receive an upfront payment of USD 3 million and is entitled to up to USD 500 million in potential milestone payments as well as a tiered single-digit royalty on product sales. Nanexa AB (publ), a leader in long-acting injectable drug delivery solutions, has today announced the signing of a license and option agreement with Moderna, Inc. (Nasdaq: MRNA). Under the agreement, Moderna receives a license to use Nanexa’s proprietary PharmaShell® drug delivery platform with its first selected compound and holds options to obtain licenses for up to four additional compounds. As part of the agreement, Nanexa will receive an upfront payment of USD 3 million. The collaboration aims to assess the potential of the PharmaShell® technology to enhance the release profile of Moderna’s selected compounds. If Moderna exercises its options for additional compounds following preclinical evaluation, each option would trigger a pre-negotiated license. The overall deal structure includes development and commercial milestone payments to Nanexa of up to a total of USD 500 million, as well as a tiered single-digit royalty on future product sales. “We are excited to partner with Moderna, a pioneer and leader in the field of mRNA medicines, to explore the potential of our PharmaShell® platform and to support the development of improved products for Moderna,” said David Westberg, CEO of Nanexa. “This agreement underscores the versatility of PharmaShell and its potential to address key challenges in the delivery of advanced biologics.” The PharmaShell® technology, based on atomic layer deposition (ALD), enables precise encapsulation of active pharmaceutical ingredients, offering tailored release profiles and improved product stability. Nanexa’s business model combines internal product development with strategic partnerships and technology licensing to leading pharmaceutical companies.
Kommentarerne ovenfor kommer fra Nordnets sociale netværk Shareville og er ikke blevet redigeret eller gennemgået af Nordnet. Det betyder ikke, at Nordnet giver investeringsrådgivning eller investeringsanbefalinger. Nordnet påtager sig ikke noget ansvar for kommentarerne.
Ordredybde
Antal
Køb
0
Sælg
Antal
0
Seneste handel
| Tid | Pris | Antal | Købere | Sælgere |
|---|---|---|---|---|
| - | - | - | - |
Højest
46,34VWAP
Lavest
43,43OmsætningAntal
485,8 10.960.692
VWAP
Højest
46,34Lavest
43,43OmsætningAntal
485,8 10.960.692
Mæglerstatistik
Ingen data fundet